DelveInsight’s ‘Pancreatic Cancer – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the pancreatic cancer historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The pancreatic cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM pancreatic cancer market size. The report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of Pancreatic Cancer Market Report:
1The total incident cases of pancreatic cancer in the 7MM were ~176,000 in 2021, which is expected to increase during the forecast period.
2 Among 7MM, the United States had the highest number of incident cases with ~60,000 cases in 2021, which is nearly 34% of the total cases of pancreatic cancer in the 7MM.
3 In EU-5, Germany had the highest number of cases with ~22,000 incident cases, followed by France with ~15,000 cases, while Spain had the least number of cases with ~8,600 cases in 2021.
4 In 2021, Japan accounted for ~43,000 incident cases of pancreatic cancer, which was approximately 25% of the total pancreatic cancer cases in 7MM.
Key Benefits of the Report:
1 The robust pipeline with novel MOA and oral ROA, increasing incidence, and effectiveness of drugs will positively drive the pancreatic cancer market.
2 The companies and academics are working to assess challenges and seek opportunities that could influence pancreatic cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
3 Major players are involved in developing therapies for pancreatic cancer. The launch of emerging therapies will significantly impact the pancreatic cancer market.
4 Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Got queries? Click here to know more about the pancreatic cancer Market Landscape
Pancreatic Cancer Overview
Pancreatic cancer begins in the tissues of the pancreas – an organ in the abdomen that lies behind the lower part of the stomach. The pancreas releases enzymes that aid digestion and produces hormones that help manage blood sugar. Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Several types of growth can occur in the pancreas, including cancerous and noncancerous tumors. The most common type of cancer that forms in the pancreas begins in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma).
Pancreatic cancer occurs when cells in the pancreas develop changes (mutations) in their DNA. A cell’s DNA contains the instructions that tell a cell what to do. These mutations tell the cells to grow uncontrollably and to continue living after normal cells would die. These accumulating cells can form a tumor. When left untreated, pancreatic cancer cells can spread to nearby organs, blood vessels, and distant body parts . Pancreatic cancer can be further divided into two larger categories: exocrine pancreatic cancer and neuroendocrine pancreatic cancer.
Pancreatic cancer symptoms may include jaundice, dark urine, weight loss, loss of appetite, fatigue, and others. It is seldom detected at its early stages when it is most curable, and this is because it often does not cause symptoms until after it has spread to other organs. It is difficult to diagnose because the symptoms of pancreatic cancer are often mistaken for those of other illnesses, such as irritable bowel syndrome. It may go undetected until it’s advanced. By the time symptoms occur, diagnosing pancreatic cancer is usually relatively straightforward; unfortunately, a cure is rarely possible.
Pancreatic cancer treatment options are chosen based on the extent of the cancer. Options may include surgery, chemotherapy, radiation therapy, targeted therapy or a combination of these.
Patients with pancreatic cancer can choose from a variety of treatments. Clinical trials are being conducted to test various treatments, some of which are standard (currently used treatments). A new treatment might replace the standard one if clinical trials reveal that it is superior to the current one. Patients might consider participating in a clinical trial. Only patients who have not begun therapy are eligible for some clinical studies.
Pancreatic Epidemiological Segmentation
1 Pancreatic Cancer Total Incident Cases
2 Pancreatic CancerMolecular Alteration-specific Incident Cases
3 Stage-specific Incident Cases
Pancreatic Cancer Market Outlook
Pancreatic cancer is enlisted as one of the most common cancers and the seventh-highest cause of cancer mortality worldwide. The incidence of pancreatic cancer is increasing in the Western world. The incidence of pancreatic adenocarcinoma is rising in the developed world, and modifiable lifestyle factors such as alcohol and obesity may play an essential role. The five-year survival from this disease is as low as 2% in some countries, despite improvements in surgical technique, chemotherapy regimens, and the introduction of neoadjuvant chemoradiotherapy. Currently, the main therapeutic approach for pancreatic cancer patients is majorly based on chemotherapy.
Pancreatic ductal adenocarcinoma (PDAC) patients constitute the major portion of the pancreatic cancer-affected population. Although advancements have been made in operative techniques and chemotherapy with time, survival rates for pancreatic cancer patients remain low. Diagnosis of pancreatic cancer in the late or advance stage i.e. Stage III, and Stage IV is the main reason for low survival. Many patients are not eligible for the treatment by this time, and in most patients, the tumor has become metastatic. Surgery can be efficiently utilized in patients with cancer in localized or regional states, and the proportion of such patients is generally low at the time of diagnosis. In the study conducted by Kasumova et al. (2017), pancreatic cancer was diagnosed in Stage I/II in only around 35% of the patients, whereas, in the remaining patients, pancreatic cancer is diagnosed at Stage III/IV. Among the patients who had disease diagnosed in Stage I/II, only 54.5% of Stage I and 43.4% of Stage II patients had undergone tumor resection. In this study, it was also reported that there had been an increase in the use of neoadjuvant therapy in Stage I and II diagnosed pancreatic cancer patients. In the case of the patients having pancreatic cancer in the advanced stage, only 68.4% and 56.9% of patients with Stage III and IV disease, respectively, received chemotherapy and/or radiation therapy.
Pancreatic Cancer Key Companies
2 Panbela Therapeutics,
4 OSE Immunotherapeutics
7 Tempus Labs
8 Lokon Pharma
Pancreatic Cancer- Therapies
Table of Contents
1. Key Insights
2. Report Introduction
3 Executive Summary of Pancreatic Cancer
4 Disease Background and Overview
5 Epidemiology and patient population
6 The United States
7 EU 5
8. Pancreatic Cancer Emerging Therapies
9. PancreaticCancer Market Outlook
10. Market Access and Reimbursement of Therapies
12. Pancreatic Cancer Report Methodology
13. DelveInsight Capabilities
15. About DelveInsight
Click here to read more about Pancreatic Cancer market Landscape
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States